NasdaqGM:VCYTBiotechs
Veracyte (VCYT) Margin Expansion And 166% Earnings Growth Test Premium Valuation Narratives
Veracyte (VCYT) just posted Q1 2026 results with revenue of US$139.1 million and basic EPS of US$0.36, while trailing 12 month figures show revenue of US$541.7 million and basic EPS of US$1.11, alongside a 166.3% year over year earnings increase and net margins at 16.2% versus 7.1% a year earlier. Over recent quarters the company has seen revenue move from US$114.5 million in Q1 2025 to US$139.1 million in Q1 2026, with basic EPS ranging from US$0.09 to US$0.52 in interim periods. This sets...